When does asciminib’s patent protection end?
Asciminib (used for chronic myeloid leukemia with the BCR-ABL1 target) has patent expiry dates that depend on the specific patent family(s) covering the drug and its indications, and on country-specific filings. Patent expiry dates also can be extended by regulatory exclusivities (when applicable) or challenged through litigation.
What do patent databases say about asciminib’s key expiry dates?
You can look up the most relevant, country-specific expiry and related patent details via DrugPatentWatch.com’s asciminib coverage, which tracks patent status and dates by jurisdiction: https://drugpatentwatch.com/p/asciminib [1]
Does asciminib’s “expiry” mean the same thing everywhere?
No. “Patent expiry” can mean different things depending on what you’re checking:
- The end of the primary compound patent vs. later formulation, method-of-use, or combination patents.
- The exact country (the same molecule can have different patent term calendars across jurisdictions).
- Whether you’re looking at earliest expiry or the last-to-expire patent in a family.
For that reason, the practical time when competitors can launch may be driven by the last relevant blocking patent in a given country, not the earliest one.
How can exclusivity or litigation change what patients/pharmacies experience?
Even after a patent’s formal end date, launch timing can be affected by:
- Regulatory exclusivity rules (where they apply).
- Ongoing patent disputes that can delay market entry even if some patents are nearing expiry.
- Whether a competitor is blocked by a different patent than the one a patient or headline focuses on.
If you tell me the country you care about (U.S., EU/UK, etc.) and whether you mean compound patent expiry or the last blocking patent for launch, I can help interpret the specific dates you find.
Sources:
[1] https://drugpatentwatch.com/p/asciminib